Associated Papers
Plant-derived Durvalumab variants show efficient PD-1/PD-L1 blockade and therapeutically favourable FcR binding.
Izadi S et al.
Plant Biotechnology Journal, 2024
Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing Variants.
Pejchal R et al.
Antibodies (basel, Switzerland), 2023
Fc-engineered antibodies with immune effector functions completely abolished.
Wilkinson I et al.
Plos One, 2021
Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in its lower hinge.
Stapleton NM et al.
Scientific Reports, 2019
Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport.
Stapleton NM et al.
Molecular Immunology, 2018
Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality.
Tam SH et al.
Antibodies (basel, Switzerland), 2017
An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability.
Borrok MJ et al.
Journal of Pharmaceutical Sciences, 2017
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.
Douthwaite J et al.
Journal of Immunology (baltimore, Md. : 1950), 2017
Select a paper to view details